Enlicitide for hypercholesterolemia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Jun 2024: Trial registered, NCT06450366
  2. 8 Jul 2024: Trial started, NCT06450366

The trials

NCT06450366: A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

State
Completed
Phase
Phase 3
People
301 taking part
Started
8 Jul 2024
Primary completion
14 Feb 2025
Arms
Enlicitide
Results
Posted on the registry
  1. 10 Jun 2024: Trial registered
  2. 8 Jul 2024: Trial started
  3. 28 Mar 2025: Trial completed
  4. 27 Mar 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.